Patient’s organoids predict response to chemotherapy
A new test based on tumour organoids can predict how patients with advanced colorectal cancer (CRC) respond to chemotherapy treatment.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
ADC Therapeutics enters licence option deal with Avacta Group
/in News/by Thomas GabrielczykADC Therapeutics SA has entered a R&D pact with Affimer developer Avacta Group plc aimed at creating and licencing Affimer-drug conjugates.
Novo Nordisk enters hemophilia gene therapy field
/in News/by Thomas GabrielczykLicencing bluebird bio’s Inc know-how and technology in one-time gene therapies Novo Nordisk A/S tries to get foothold in the emerging hemophilia A gene therapy market.
Evotec and Celmatix enter strategic partnership
/in News/by Thomas GabrielczykEvotec SE has expanded its drug discovery customer base with US women’s health specialist Celmatix Inc.
Researchers unravel how ADEP antibiotics work
/in News/by Thomas GabrielczykGerman researchers have unraveled the mechanism of a ADEPs, a novel class of antibiotics, allowing pharmacological optimisation.
New method allows tracking of HIV
/in News/by Thomas GabrielczykA new method allows real-time-visualisation of how the HI virus spreads between living T helper cells and which molecules it requires for this purpose.
Rottapharm Biotech: POC in osteoarthritis pain
/in News/by Thomas GabrielczykRottapharm Biotech (Monza, Italy) has published detailed results from a clinical Phase II trial of CR4056 in chronic pain from knee osteoarthritis.
Creoptix AG closes CHF8m financing round
/in News/by Thomas GabrielczykSwiss drug discovery analytics specialist Creoptix AG has raised CHF8m in a Series C financing for commercial expansion.
AMR: GARDP and Entasis Therapeutics start pivotal study
/in News/by Thomas GabrielczykEntasis Therapeutics Inc (Waltham, USA) and non for profit organisation GARDP (Geneva, Switzerland) have initiated Phase III testing of the novel antibiotic zoliflodacin to treat infections with the WHO priority […]
BASF broadens biotech business by Isobionics acquisition
/in News/by Thomas GabrielczykBASF SE has strengthened its capabilities in recombinant production of natural ingredients by acquiring Dutch Isobionics BV and collaborating with Conagen Inc.